Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06905054 · ClinicalTrials.gov registry record · Phase 2
Pharmacologic Approaches to Preventing Primary Sclerosing Cholangitis Recurrence After Liver Transplantation
A Phase 2 study of Primary Sclerosing Cholangitis and Liver Transplant, Complications, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT06905054 is a Phase 2 study of Primary Sclerosing Cholangitis and Liver Transplant, Complications that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 80 participants, below the 549-participant average among 23 other Primary Sclerosing Cholangitis trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06905054, a Phase 2 study of Primary Sclerosing Cholangitis and Liver Transplant, Complications, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
This study aims to determine the efficacy of 36 months once-daily fenofibrate in preventing clinically-detectable recurrence of primary sclerosing cholangitis after liver transplantation, compared with a historical control cohort that was not treated with
Conditions Studied
Interventions
- DRUG Fenofibrate (drug)
- DIAGNOSTIC_TEST Blood draw for the laboratory assessment
- DIAGNOSTIC_TEST MRI using a hepatobiliary phase contrast agent (Gd-EOB-DPTA)
Study Locations (1)
Arizona
- Mayo Clinic in Arizona - Scottsdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2025-04-15 |
| Est. Completion | 2028-07-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06905054
The ClinicalTrials.gov registry entry for NCT06905054 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 549-participant average among 23 other Primary Sclerosing Cholangitis trials with a reported enrollment target (85% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Primary Sclerosing Cholangitis appearing as the primary indexed condition, and to 3 interventions - of which Fenofibrate (drug) is the first listed.
NCT06905054 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.
Frequently Asked Questions
What is clinical trial NCT06905054 about?
NCT06905054 is a clinical study titled "Pharmacologic Approaches to Preventing Primary Sclerosing Cholangitis Recurrence After Liver Transplantation". This study aims to determine the efficacy of 36 months once-daily fenofibrate in preventing clinically-detectable recurrence of primary sclerosing cholangitis after liver transplantation, compared with a historical control cohort that was not treated with
What is the current status of trial NCT06905054?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2025-04-15. Estimated completion is 2028-07-01.
What conditions does trial NCT06905054 study?
This clinical trial studies the following conditions: Primary Sclerosing Cholangitis, Liver Transplant, Complications, PSC, Biliary Strictures.
What interventions are being tested in trial NCT06905054?
The interventions under investigation include: Fenofibrate (drug) (DRUG), Blood draw for the laboratory assessment (DIAGNOSTIC_TEST), MRI using a hepatobiliary phase contrast agent (Gd-EOB-DPTA) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06905054?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06905054 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Sclerosing Cholangitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Oral Hymecromone to Treat Adolescents and Adults With Primary Sclerosing Cholangitis.
RECRUITING · Phase 2
-
Detoxification of the Liver In PSC (Dolphin)
RECRUITING · Phase 2
-
A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis.
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)
ACTIVE NOT RECRUITING · Phase 2
-
Sulfasalazine for the Treatment of Primary Sclerosing Cholangitis
COMPLETED · Phase 2
-
A Study of NGM282 in Patients With Primary Sclerosing Cholangitis
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.